Top entities: Immunome, United States — Food and Drug Administration, European Union — European Medicines Agency, Clay Siegall, American Society of Clinical Oncology.

What category does this event fall under?

Regulatory — classified as regulatory submission.

What is the sentiment of coverage?

Aggregate sentiment score: 40 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

United States — Food and Drug Administration accepted NDA Immunome · Immunome reported positive trial results · Immunome plans to submit MAA European Union — European Medicines Agency

Is this event still developing?

This is an active story, last updated Jul 08, 2026. Coverage continues to evolve.

Regulatory regulatory submission

FDA accepts Immunome NDA for varegacestat

Q: When did this event occur?

First reported Jul 08, 2026; last updated Jul 08, 2026.

Q: What is the market impact?

General. The FDA acceptance of Immunome's NDA for varegacestat is a positive regulatory milestone, potentially leading to a new treatment option for desmoid tumors.

Analysis based on 6 articles · First reported Jul 08, 2026 · Last updated Jul 08, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The FDA acceptance of Immunome's NDA for varegacestat is a positive regulatory milestone, potentially leading to a new treatment option for desmoid tumors. However, the stock decline suggests some market skepticism or profit-taking, and the final approval decision is still pending.

Biotechnology Pharmaceuticals

Event Summary

Immunome announced that the U.S. United States — Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for varegacestat, an investigational oral gamma secretase inhibitor for treating adults with desmoid tumors. The FDA set a PDUFA target action date of April 28, 2027. The NDA is based on positive Phase 3 RINGSIDE trial results showing an 84% reduction in risk of disease progression or death, a 56% objective response rate, and improved pain intensity. Immunome plans to submit a Marketing Authorization Application to the European Union — European Medicines Agency by end of 2026. The company's stock fell 5.36% in pre-market trading.

Key Actions

100 United States — Food and Drug Administration accepted NDA Immunome

90 Immunome reported positive trial results

60 Immunome plans to submit MAA European Union — European Medicines Agency

Entities Involved

stock

Immunome

Immunome is the sponsor of the NDA and stands to benefit if varegacestat is approved, potentially generating significant revenue from a novel oral therapy for desmoid tumors.

Importance 100.0 Sentiment 40.0

govactor

United States — Food and Drug Administration

The FDA accepted the NDA for review and will decide on approval by April 28, 2027, playing a critical regulatory role in the event.

Importance 80.0 Sentiment 0.0

govactor

European Union — European Medicines Agency

Immunome plans to submit a Marketing Authorization Application to the EMA by end of 2026, making the EMA a future regulatory body for varegacestat in Europe.

Importance 40.0 Sentiment 0.0

per

Clay Siegall

As CEO of Immunome, Clay Siegall announced the milestone and expressed confidence in varegacestat's potential, representing the company's leadership.

Importance 30.0 Sentiment 0.0

ngo

American Society of Clinical Oncology

The RINGSIDE trial results were presented at the 2026 ASCO Annual Meeting, providing a platform for data dissemination.

Importance 20.0 Sentiment 0.0

Relationships

United States — Food and Drug Administration related ↔ European Union — European Medicines Agency

United States — Food and Drug Administration related ↔ American Society of Clinical Oncology

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard